ClinicalTrials.gg
RecruitingNCT07459907GRAZ-GDMUpdated Apr 13, 2026

Gestational Diabetes and Health Outcomes in Mothers and Babies

An observational study in Gestational Diabetes Mellitus (GDM) and Pregnancy, sponsored by Medical University of Graz. Recruiting at 1 site in Austria. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Medical University of Graz · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Diabetes, Gestational with a site in Austria — 4 open to participants now, 5 under way, none of them phase 3. Diabetes, Gestational · Austria.

Started
2025
with 1 other
Observational
6 of 11
3 open now
Registered
10th of 11
by date
Lead sponsor
3 of 11
Medical University of Graz

Among the 11 studies in Diabetes, Gestational with a site in Austria, this one is one of 2 that started in 2025, is one of 6 observational ones, and was the 10th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

4 of the 11 studies in Diabetes, Gestational with a site in Austria are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetes, Gestational with a site in Austria, or all of them as a file.
02

Study summary

Gestational diabetes mellitus (GDM) is a common pregnancy complication characterized by impaired glucose metabolism and increased insulin resistance. GDM is associated with adverse pregnancy outcomes and an increased long-term risk of metabolic and cardiovascular disease for both mother and offspring.

This prospective observational cohort study aims to establish a longitudinal pregnancy and birth cohort of women diagnosed with GDM. Pregnant women with a positive 75 g oral glucose tolerance test (OGTT) between gestational weeks 24 and 28 will be recruited after diagnosis and followed through late pregnancy, delivery, and early postpartum.

Participants will undergo two study visits during pregnancy, sample collection at delivery, and one postpartum visit 8-12 weeks after birth. Clinical data, physical measurements, questionnaire-based information, and biological samples will be collected from mothers and infants to enable comprehensive phenotyping of GDM pregnancies.

Data and biosamples from this cohort will be used for descriptive and hypothesis-driven analyses and may be compared with data from an existing longitudinal cohort of healthy pregnancies to support interpretation of GDM-related changes.

Read the detailed description

Gestational diabetes mellitus (GDM) develops when physiological insulin resistance during pregnancy exceeds adaptive capacity, resulting in impaired glucose regulation. GDM is associated with increased perinatal morbidity and elevated long-term risk for metabolic and cardiovascular disease in both mothers and offspring. Despite its clinical relevance, the biological mechanisms underlying GDM and its long-term consequences are incompletely understood.

This prospective, monocentric observational cohort study is designed to establish a well-characterized longitudinal pregnancy and birth cohort of women diagnosed with GDM. The primary objective is to collect clinical data and biological samples across pregnancy, delivery, and early postpartum to support detailed phenotyping of GDM pregnancies and early-life outcomes.

Approximately 100 pregnant women with a confirmed diagnosis of GDM will be recruited per year at the Department of Obstetrics and Gynecology. Eligible participants are women aged 18 years or older with an ongoing pregnancy prior to gestational week 32 and a positive 75 g OGTT performed as part of routine clinical care. Women with major fetal anomalies are excluded.

Study participation includes four time points: 1.) a visit following GDM diagnosis (approximately gestational weeks 26-30), 2.) a late pregnancy visit (approximately weeks 34-37), 3.) sample and clinical data collection at delivery, and 4) a postpartum follow-up visit 8-12 weeks after birth.

At each study visit, standardized clinical assessments, physical measurements, and questionnaire-based information will be collected. Maternal assessments include anthropometry, body composition, blood pressure, and selected non-invasive cardiovascular and metabolic measurements. Fetal growth is assessed by routine obstetric ultrasound. At delivery, perinatal samples such as placenta, umbilical cord, and cord blood are collected. Postnatal assessments include maternal and infant anthropometry and selected cardiovascular measurements where applicable.

Biological samples collected longitudinally may include blood, urine, saliva, vaginal swabs, breast milk, placental tissue, umbilical cord tissue, and umbilical cord blood. Samples are processed and stored in a biobank for future analyses following separate ethical approvals. Clinical metadata include pregnancy outcomes, GDM treatment, delivery characteristics, and neonatal outcomes.

Lifestyle and behavioral factors, including nutrition and physical activity, are assessed using standardized questionnaires. Data are pseudonymized and handled in accordance with applicable data protection regulations.

This study is designed as a cohort and sample collection platform.

For contextual comparison, data and biosamples from an existing longitudinal cohort of healthy pregnancies will be used where appropriate. Alignment of visit timing and data collection procedures allows comparative analyses between GDM and normoglycemic pregnancies.

03

Conditions studied

  • Gestational Diabetes Mellitus (GDM)
  • Pregnancy

Keywords

  • GDM
  • Insulin resistance
  • Glucose metabolism
  • Cardiometabolic risk
  • Pregnancy outcomes
  • Pregnancy phenotyping
  • Maternal and infant health
  • Pregnancy
  • Post-partum follow up
  • Longitudinal cohort
  • Fetal growth
  • Neonatal adiposity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population consists of pregnant women diagnosed with gestational diabetes mellitus (GDM) based on a positive 75 g oral glucose tolerance test performed as part of routine clinical care between gestational weeks 24 and 28. Participants are recruited after diagnosis at a tertiary care obstetric center and followed through late pregnancy, delivery, and early postpartum.

Eligible participants are adults aged 18 years or older with an ongoing singleton pregnancy prior to gestational week 32. Women with major fetal anomalies are excluded. In addition, a non-pregnant reference cohort of healthy adult males and non-pregnant females may be recruited for selected analyses to provide pregnancy- and sex-independent reference data.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ongoing pregnancy prior to the 32nd gestational week and a positive GDM screening

Exclusion criteria

Exclusion Criteria:

  • gestational age 32nd gestational week
  • fetal genetic anomalies /malformation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Maternal metabolic and cardiometabolic phenotype: Adiposity

    Measured as fat mass and fat-free mass by air displacement plethysmography longitudinally after gestational diabetes diagnosis and during early postpartum follow-up.

    Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.

  2. Maternal metabolic and cardiometabolic phenotype: fasting glucose

    Fasting blood glucose as measured in mg/mL from NaF blood tubes longitudinally after gestational diabetes diagnosis and during early postpartum follow-up.

    Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.

  3. Maternal metabolic and cardiometabolic phenotype: blood pressure

    Resting systolic and diastolic blood pressure measured using standardized clinical procedures after gestational diabetes diagnosis and during early postpartum follow-up.

    Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.

  4. Maternal metabolic and cardiometabolic phenotype: cytokine profile

    Serum cytokine will be analysed by multiplexing after gestational diabetes diagnosis and during early postpartum follow-up.

    Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.

  5. Maternal metabolic and cardiometabolic phenotype: lipid profile (triglycerides, phospholipids, free, fatty acids, HDL/LDL/total cholesterol)

    Lipid profiles are measured after gestational diabetes diagnosis and during early postpartum follow-up.

    Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.

  6. Maternal metabolic and cardiometabolic phenotype: endothelial function

    Endothelial function measured as pulse wave velocity using a Vicorder® after gestational diabetes diagnosis and during early postpartum follow-up.

    Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.

  7. Infant outcomes: adiposity

    Measured as fat mass and fat-free mass by air displacement plethysmography (via PEAPOD)

    Time frame: At birth and at 8-12 weeks postpartum.

  8. Infant outcomes: Neonatal C-peptide in cord blood

    Concentrations of C-peptide in cord blood serum

    Time frame: At birth

  9. Infant outcomes: Neonatal glucose in cord blood

    Concentrations of glucose in cord blood serum

    Time frame: At birth

07

Study locations

1 of 1 sites recruiting
  • Department of Obstetrics and Gynecology, Medical University of Graz
    Graz, 8036, Austria
    Recruiting
    • Evelyn Jantscher-Krenn, PhD · Contactevelyn.jantscher-krenn@medunigraz.at · +43 316 385 80076
    • Christina Stern, Dr. med. · Contactchristina.stern@medunigraz.at
    • Christina Stern, Dr. med. · Principal investigator
    • Evelyn Jantscher-Krenn, PhD · Principal investigator
    • Ursula Hiden, PhD · Principal investigator
    • Federica Piani, DM, PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2030, 60 months after the start.

Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 60 months is above that.

Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 10, 2026
StartActual
Jun 15, 2025
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2035
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07459907
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Jun 15, 2025
Primary completion
Jun 2030 (estimated)
Completion
Jun 2035 (estimated)
Last update
Apr 13, 2026

Study contacts

Evelyn Jantscher-Krenn, PhD
Contact
evelyn.jantscher-krenn@medunigraz.at
+43 316 385 80076
Christina Stern, Dr. med.
Contact
christina.stern@medunigraz.at
+43 316 385 86306
Christina Stern, Dr. med.
principal investigator · Medical University of Graz
Ursula Hiden, PhD
principal investigator · Medical University of Graz
Evelyn Jantscher-Krenn, PhD
principal investigator · Medical University of Graz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion